Trade Olema Pharmaceuticals, Inc. - OLMA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 15.19 |
| Open* | 14.77 |
| 1-Year Change* | 453.18% |
| Day's Range* | 12.85 - 15.22 |
| 52 wk Range | 2.19-17.79 |
| Average Volume (10 days) | 616.10K |
| Average Volume (3 months) | 8.57M |
| Market Cap | 777.73M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 54.77M |
| Revenue | N/A |
| EPS | -2.32 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Mar 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 4, 2023 | 15.19 | 0.61 | 4.18% | 14.58 | 15.44 | 14.42 |
| Dec 1, 2023 | 14.55 | 0.88 | 6.44% | 13.67 | 14.57 | 13.50 |
| Nov 30, 2023 | 13.93 | 0.91 | 6.99% | 13.02 | 14.60 | 12.24 |
| Nov 29, 2023 | 13.12 | -0.50 | -3.67% | 13.62 | 13.76 | 12.87 |
| Nov 28, 2023 | 13.51 | 0.35 | 2.66% | 13.16 | 13.51 | 12.11 |
| Nov 27, 2023 | 13.16 | -1.11 | -7.78% | 14.27 | 14.37 | 13.07 |
| Nov 24, 2023 | 13.84 | 0.24 | 1.76% | 13.60 | 14.06 | 13.60 |
| Nov 22, 2023 | 13.71 | -0.46 | -3.25% | 14.17 | 14.40 | 13.59 |
| Nov 21, 2023 | 14.16 | -1.66 | -10.49% | 15.82 | 15.82 | 14.14 |
| Nov 20, 2023 | 15.90 | -0.01 | -0.06% | 15.91 | 16.06 | 15.48 |
| Nov 17, 2023 | 15.87 | -0.88 | -5.25% | 16.75 | 16.91 | 15.70 |
| Nov 16, 2023 | 16.77 | -0.10 | -0.59% | 16.87 | 16.87 | 15.93 |
| Nov 15, 2023 | 16.77 | 0.80 | 5.01% | 15.97 | 17.11 | 15.97 |
| Nov 14, 2023 | 15.83 | 0.70 | 4.63% | 15.13 | 16.12 | 14.98 |
| Nov 13, 2023 | 14.70 | -0.77 | -4.98% | 15.47 | 15.49 | 14.57 |
| Nov 10, 2023 | 15.79 | -0.38 | -2.35% | 16.17 | 16.57 | 15.27 |
| Nov 9, 2023 | 16.09 | -0.78 | -4.62% | 16.87 | 17.24 | 15.89 |
| Nov 8, 2023 | 17.07 | 0.45 | 2.71% | 16.62 | 17.62 | 15.47 |
| Nov 7, 2023 | 16.57 | 1.52 | 10.10% | 15.05 | 16.71 | 15.05 |
| Nov 6, 2023 | 15.00 | -1.62 | -9.75% | 16.62 | 16.72 | 13.53 |
Olema Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Friday, December 8, 2023 | ||
| Time (UTC) 13:00 | Country US
| Event Olema Pharmaceuticals Inc to Host Call for Analysts and Investors Olema Pharmaceuticals Inc to Host Call for Analysts and InvestorsForecast -Previous - |
| Thursday, March 7, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 Olema Pharmaceuticals Inc Earnings Release Q4 2023 Olema Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 106.988 | 71.491 | 21.528 | 4.323 | 2.173 |
| Selling/General/Admin. Expenses, Total | 24.714 | 20.391 | 7.824 | 0.403 | 0.386 |
| Research & Development | 82.274 | 51.1 | 13.704 | 3.92 | 1.693 |
| Unusual Expense (Income) | 0 | 0.094 | |||
| Operating Income | -106.988 | -71.491 | -21.528 | -4.323 | -2.173 |
| Interest Income (Expense), Net Non-Operating | 2.228 | 0.442 | -0.593 | 0.007 | -0.024 |
| Other, Net | -0.027 | -0.047 | 0 | 0 | |
| Net Income Before Taxes | -104.787 | -71.096 | -22.121 | -4.316 | -2.197 |
| Net Income After Taxes | -104.787 | -71.096 | -22.121 | -4.316 | -2.197 |
| Net Income Before Extra. Items | -104.787 | -71.096 | -22.121 | -4.316 | -2.197 |
| Net Income | -104.787 | -71.096 | -22.121 | -4.316 | -2.197 |
| Total Adjustments to Net Income | 0 | -1.869 | 0 | 0 | |
| Income Available to Common Excl. Extra. Items | -104.787 | -71.096 | -23.99 | -4.316 | -2.197 |
| Income Available to Common Incl. Extra. Items | -104.787 | -71.096 | -23.99 | -4.316 | -2.197 |
| Diluted Net Income | -104.787 | -71.096 | -23.99 | -4.316 | -2.197 |
| Diluted Weighted Average Shares | 39.9955 | 39.5243 | 38.5197 | 38.5197 | 38.5197 |
| Diluted EPS Excluding Extraordinary Items | -2.61997 | -1.79879 | -0.6228 | -0.11205 | -0.05704 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -2.61997 | -1.79879 | -0.6228 | -0.11205 | -0.0546 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 21.601 | 29.602 | 27.219 | 23.222 | 33.293 |
| Selling/General/Admin. Expenses, Total | 3.612 | 6.776 | 5.635 | 5.595 | 6.239 |
| Research & Development | 17.989 | 22.826 | 21.584 | 17.627 | 27.054 |
| Operating Income | -21.601 | -29.602 | -27.219 | -23.222 | -33.293 |
| Interest Income (Expense), Net Non-Operating | 1.55 | 1.305 | 0.973 | 0.622 | 0.415 |
| Net Income Before Taxes | -20.095 | -28.286 | -26.179 | -22.72 | -32.858 |
| Net Income After Taxes | -20.095 | -28.286 | -26.179 | -22.72 | -32.858 |
| Net Income Before Extra. Items | -20.095 | -28.286 | -26.179 | -22.72 | -32.858 |
| Net Income | -20.095 | -28.286 | -26.179 | -22.72 | -32.858 |
| Income Available to Common Excl. Extra. Items | -20.095 | -28.286 | -26.179 | -22.72 | -32.858 |
| Income Available to Common Incl. Extra. Items | -20.095 | -28.286 | -26.179 | -22.72 | -32.858 |
| Diluted Net Income | -20.095 | -28.286 | -26.179 | -22.72 | -32.858 |
| Diluted Weighted Average Shares | 40.7203 | 40.3545 | 40.1906 | 40.0362 | 39.9182 |
| Diluted EPS Excluding Extraordinary Items | -0.49349 | -0.70094 | -0.65137 | -0.56749 | -0.82313 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.49349 | -0.70094 | -0.65137 | -0.56749 | -0.82313 |
| Other, Net | -0.044 | 0.011 | 0.067 | -0.12 | 0.02 |
| Total Adjustments to Net Income |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 208.899 | 290.685 | 342.137 | 0.103 | 3.242 |
| Cash and Short Term Investments | 204.421 | 287.25 | 338.549 | 0.068 | 3.149 |
| Cash & Equivalents | 23.702 | 13.812 | 338.549 | 0.068 | 3.149 |
| Prepaid Expenses | 2.655 | 3.212 | 3.439 | 0 | 0 |
| Other Current Assets, Total | 1.504 | 0.223 | 0.149 | 0.035 | 0.093 |
| Total Assets | 215.645 | 295.945 | 342.722 | 0.132 | 3.271 |
| Property/Plant/Equipment, Total - Net | 3.975 | 4.72 | 0.075 | 0.026 | 0.026 |
| Property/Plant/Equipment, Total - Gross | 4.556 | 4.944 | 0.106 | 0.097 | |
| Accumulated Depreciation, Total | -0.581 | -0.224 | -0.08 | -0.071 | |
| Other Long Term Assets, Total | 2.771 | 0.54 | 0.51 | 0.003 | 0.003 |
| Total Current Liabilities | 16.549 | 9.019 | 4.585 | 1.378 | 0.201 |
| Accounts Payable | 0.374 | 0.023 | 0.719 | 0.935 | 0.116 |
| Accrued Expenses | 16.025 | 8.53 | 3.494 | 0 | 0 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.15 | 0.466 | 0.372 | 0.443 | 0.085 |
| Total Liabilities | 18.099 | 11.377 | 4.585 | 1.378 | 0.201 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 197.546 | 284.568 | 338.137 | -1.246 | 3.07 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 9.348 | 9.348 |
| Common Stock | 0.003 | 0.003 | 0.003 | 0 | 0 |
| Additional Paid-In Capital | 408.333 | 388.904 | 371.228 | 0.168 | 0.168 |
| Retained Earnings (Accumulated Deficit) | -208.977 | -104.19 | -33.094 | -10.762 | -6.446 |
| Total Liabilities & Shareholders’ Equity | 215.645 | 295.945 | 342.722 | 0.132 | 3.271 |
| Total Common Shares Outstanding | 40.2871 | 39.7973 | 39.3082 | 38.5197 | 38.5197 |
| Short Term Investments | 180.719 | 273.438 | |||
| Other Liabilities, Total | 1.55 | 2.358 | |||
| Other Equity, Total | -1.813 | -0.149 | |||
| Total Receivables, Net | 0.319 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 282.008 | 171.509 | 189.397 | 208.899 | 225.058 |
| Cash and Short Term Investments | 276.901 | 167.444 | 185.954 | 204.421 | 222.6 |
| Cash & Equivalents | 117.407 | 34.958 | 40.918 | 23.702 | 26.804 |
| Short Term Investments | 159.494 | 132.486 | 145.036 | 180.719 | 195.796 |
| Prepaid Expenses | 4.414 | 3.607 | 3.069 | 2.655 | 1.298 |
| Other Current Assets, Total | 0.274 | 0.237 | 0.072 | 1.504 | 1.16 |
| Total Assets | 292.799 | 177.624 | 195.768 | 215.645 | 231.997 |
| Property/Plant/Equipment, Total - Net | 3.614 | 3.211 | 3.6 | 3.975 | 4.168 |
| Property/Plant/Equipment, Total - Gross | 4.312 | 3.955 | 4.281 | 4.556 | 4.652 |
| Accumulated Depreciation, Total | -0.698 | -0.744 | -0.681 | -0.581 | -0.484 |
| Other Long Term Assets, Total | 7.177 | 2.904 | 2.771 | 2.771 | 2.771 |
| Total Current Liabilities | 15.966 | 14.831 | 19.41 | 16.549 | 12.552 |
| Accounts Payable | 2.207 | 1.625 | 0.681 | 0.374 | 0.014 |
| Accrued Expenses | 13.702 | 13.094 | 18.569 | 16.025 | 12.278 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.057 | 0.112 | 0.16 | 0.15 | 0.26 |
| Total Liabilities | 17.665 | 16.041 | 20.793 | 18.099 | 14.298 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 275.134 | 161.583 | 174.975 | 197.546 | 217.699 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.004 | 0.003 | 0.003 | 0.003 | 0.003 |
| Additional Paid-In Capital | 554.231 | 419.456 | 413.213 | 408.333 | 403.168 |
| Retained Earnings (Accumulated Deficit) | -278.86 | -257.358 | -237.263 | -208.977 | -182.798 |
| Other Equity, Total | -0.241 | -0.518 | -0.978 | -1.813 | -2.674 |
| Total Liabilities & Shareholders’ Equity | 292.799 | 177.624 | 195.768 | 215.645 | 231.997 |
| Total Common Shares Outstanding | 54.6015 | 41.3244 | 40.4383 | 40.2871 | 40.0846 |
| Other Liabilities, Total | 1.699 | 1.21 | 1.383 | 1.55 | 1.746 |
| Total Receivables, Net | 0.419 | 0.221 | 0.302 | 0.319 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -104.787 | -71.096 | -22.121 | -4.316 | -2.197 |
| Cash From Operating Activities | -82.065 | -50.69 | -19.866 | -3.081 | -2.176 |
| Cash From Operating Activities | 0.357 | 0.163 | 0.011 | 0.009 | 0.008 |
| Non-Cash Items | 19.343 | 17.413 | 3.749 | 0 | 0.123 |
| Changes in Working Capital | 3.022 | 2.83 | -1.505 | 1.226 | -0.11 |
| Cash From Investing Activities | 91.479 | -275.438 | -0.056 | 0 | 0 |
| Capital Expenditures | -0.363 | -1.575 | -0.056 | 0 | 0 |
| Cash From Financing Activities | 0.476 | 1.391 | 358.403 | 0 | 5.254 |
| Financing Cash Flow Items | 0 | 0 | |||
| Issuance (Retirement) of Stock, Net | 0.476 | 1.391 | 355.315 | 0 | 4.931 |
| Issuance (Retirement) of Debt, Net | 0 | 3.088 | 0 | 0.323 | |
| Net Change in Cash | 9.89 | -324.737 | 338.481 | -3.081 | 3.078 |
| Other Investing Cash Flow Items, Total | 91.842 | -273.863 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -28.286 | -104.787 | -78.608 | -55.888 | -23.03 |
| Cash From Operating Activities | -20.391 | -82.065 | -62.354 | -44.362 | -17.903 |
| Cash From Operating Activities | 0.1 | 0.357 | 0.26 | 0.169 | 0.084 |
| Non-Cash Items | 4.088 | 19.343 | 14.727 | 10.315 | 5.294 |
| Changes in Working Capital | 3.707 | 3.022 | 1.267 | 1.042 | -0.251 |
| Cash From Investing Activities | 37.387 | 91.479 | 75.143 | 54.979 | 25.567 |
| Capital Expenditures | 0 | -0.363 | -0.19 | -0.051 | -0.03 |
| Other Investing Cash Flow Items, Total | 37.387 | 91.842 | 75.333 | 55.03 | 25.597 |
| Net Change in Cash | 17.216 | 9.89 | 12.992 | 10.714 | 7.697 |
| Cash From Financing Activities | 0.22 | 0.476 | 0.203 | 0.097 | 0.033 |
| Issuance (Retirement) of Stock, Net | 0.22 | 0.476 | 0.203 | 0.097 | 0.033 |
| Financing Cash Flow Items | |||||
| Issuance (Retirement) of Debt, Net |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| BVF Partners L.P. | Hedge Fund | 16.926 | 9235449 | 1623946 | 2023-09-14 | LOW |
| Paradigm BioCapital Advisors LP | Investment Advisor | 14.3018 | 7803600 | 4072554 | 2023-09-12 | MED |
| Logos Global Management LLC | Investment Advisor | 6.8615 | 3743875 | -14943 | 2023-06-30 | HIGH |
| Cormorant Asset Management, LP | Hedge Fund | 5.6484 | 3082000 | 0 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.4435 | 1878878 | 1210899 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.0671 | 1673522 | 165755 | 2023-06-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 2.937 | 1602556 | 1389244 | 2023-06-30 | LOW |
| Vivo Capital, LLC | Venture Capital | 2.4545 | 1339271 | -350244 | 2023-06-30 | LOW |
| Kynam Capital Management LP | Hedge Fund | 2.3905 | 1304332 | -707521 | 2023-06-30 | MED |
| Harmon (Cyrus) | Individual Investor | 2.0082 | 1095742 | -35000 | 2023-09-29 | LOW |
| Sectoral Asset Management Inc. | Investment Advisor/Hedge Fund | 1.1882 | 648353 | -347556 | 2023-06-30 | MED |
| Citadel Advisors LLC | Hedge Fund | 1.1665 | 636475 | -594041 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.1131 | 607340 | 257394 | 2023-06-30 | LOW |
| Woodline Partners LP | Hedge Fund | 1.0777 | 588052 | 588052 | 2023-06-30 | HIGH |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 1.0617 | 579309 | 3409 | 2023-06-30 | MED |
| Myles (David C Ph.D.) | Individual Investor | 1.0297 | 561821 | -20000 | 2023-09-19 | |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.9085 | 495700 | 374519 | 2023-06-30 | LOW |
| Rappaport (Andrew) | Individual Investor | 0.8816 | 481014 | 0 | 2023-04-25 | |
| BioImpact Capital LLC | Investment Advisor/Hedge Fund | 0.8476 | 462500 | 462500 | 2023-06-30 | MED |
| Kovacs Shane William Charles | Individual Investor | 0.7261 | 396197 | 15000 | 2023-04-25 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Olema Pharmaceuticals, Inc. Company profile
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It was designed based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. It’s been ongoing Phase 1/2 clinical trial, and in Phase 1b combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Olema Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased from $24M to $71.1M. Higher net loss reflects Research and development increase from $11.7M to $41.8M (expense), Stock-based Compensation in R&D increase from $2M to $9.3M (expense), General and administrative - Balancing increase from $6.7M to $13.8M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
780 Brannan Street
SAN FRANCISCO
CALIFORNIA 94103
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com